Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Ixaka France has 1 pending office action in Biotechnology & Pharmaceuticals. Its pending work is handled by 1 distinct examiner within 1 distinct art unit, creating a compact prosecution profile. MATALKAH, FATIMAH KHALAF is the busiest examiner, with 1 pending matter.
The available data points to a single examination channel rather than a portfolio spread across several technical units. Counsel can focus review on the cited matter, the examiner’s practice, and the governing art-unit context. Any prosecution plan should preserve consistency between claim scope, supporting disclosure, and the biotechnology and pharmaceutical subject matter under examination.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MATALKAH, FATIMAH KHALAF | 1 | 55.8% | +27.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17777106 | Polymer-Encapsulated Viral Vectors for In Vivo Genetic Therapy | MATALKAH, FATIMAH KHALAF | — |
| Art Unit | Apps |
|---|---|
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17777106 | Polymer-Encapsulated Viral Vectors for In Vivo Genetic Therapy | MATALKAH, FATIMAH KHALAF | 1638 | §103 | Non-Final OA | — | Pending | May 16, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialIxaka France has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Fatimah Khalaf Matalkah has the most, with 1 of Ixaka France's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
